PH12022550347A1 - Oral pharmaceutical composition - Google Patents

Oral pharmaceutical composition

Info

Publication number
PH12022550347A1
PH12022550347A1 PH1/2022/550347A PH12022550347A PH12022550347A1 PH 12022550347 A1 PH12022550347 A1 PH 12022550347A1 PH 12022550347 A PH12022550347 A PH 12022550347A PH 12022550347 A1 PH12022550347 A1 PH 12022550347A1
Authority
PH
Philippines
Prior art keywords
pharmaceutical composition
oral pharmaceutical
active ingredient
release
effective amount
Prior art date
Application number
PH1/2022/550347A
Other languages
English (en)
Inventor
Ryuta Aono
Takuya Fujii
Naoki Kamada
Ryohei Togashi
Xinyu Wang
Motoyasu Yoshimura
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of PH12022550347A1 publication Critical patent/PH12022550347A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PH1/2022/550347A 2019-08-13 2020-08-13 Oral pharmaceutical composition PH12022550347A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP2019/031895 WO2021029020A1 (ja) 2019-08-13 2019-08-13 経口医薬組成物
PCT/JP2020/030776 WO2021029429A1 (ja) 2019-08-13 2020-08-13 経口医薬組成物

Publications (1)

Publication Number Publication Date
PH12022550347A1 true PH12022550347A1 (en) 2022-12-12

Family

ID=74569440

Family Applications (2)

Application Number Title Priority Date Filing Date
PH1/2022/550347A PH12022550347A1 (en) 2019-08-13 2020-08-13 Oral pharmaceutical composition
PH1/2022/550349A PH12022550349B1 (en) 2019-08-13 2020-08-13 Oral pharmaceutical composition containing heterocyclic compound

Family Applications After (1)

Application Number Title Priority Date Filing Date
PH1/2022/550349A PH12022550349B1 (en) 2019-08-13 2020-08-13 Oral pharmaceutical composition containing heterocyclic compound

Country Status (15)

Country Link
US (4) US20220273647A1 (https=)
EP (2) EP4015001A4 (https=)
JP (7) JPWO2021029020A1 (https=)
KR (2) KR20220046625A (https=)
CN (2) CN114222562A (https=)
AU (2) AU2020328351B2 (https=)
BR (2) BR112022002433A2 (https=)
CA (2) CA3150751A1 (https=)
IL (2) IL290469B2 (https=)
MX (3) MX2022001758A (https=)
MY (2) MY208261A (https=)
PH (2) PH12022550347A1 (https=)
TW (2) TWI870441B (https=)
WO (3) WO2021029020A1 (https=)
ZA (2) ZA202202319B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021029020A1 (ja) * 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物
CN118742293A (zh) * 2022-01-31 2024-10-01 住友精化株式会社 药物控释制剂用组合物和药物控释制剂
JP2023173950A (ja) * 2022-05-27 2023-12-07 同仁医薬化工株式会社 経口液剤
AU2024247059A1 (en) * 2023-03-29 2025-10-30 Merck Sharp & Dohme (Uk) Limited Controlled release pde10a formulations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (https=) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3865108A (en) 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
TWI632921B (zh) * 2011-10-19 2018-08-21 大塚製藥股份有限公司 口服溶液
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
EP2911670A1 (en) * 2012-10-25 2015-09-02 Otsuka Pharmaceutical Co., Ltd. Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof
CN106667969A (zh) * 2017-02-23 2017-05-17 佛山市弘泰药物研发有限公司 一种依匹哌唑缓释胶囊及其制备方法
JP6886654B2 (ja) 2017-04-11 2021-06-16 学校法人帝京大学 抗カンジダ活性組成物
WO2021029020A1 (ja) * 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物

Also Published As

Publication number Publication date
CN114222575A (zh) 2022-03-22
MX2022001758A (es) 2022-05-13
JPWO2021029020A1 (https=) 2021-02-18
PH12022550349B1 (en) 2024-03-06
BR112022002433A2 (pt) 2022-12-13
MY208261A (en) 2025-04-29
MY208267A (en) 2025-04-29
JPWO2021029429A1 (https=) 2021-02-18
AU2020327792A1 (en) 2022-03-24
TW202120090A (zh) 2021-06-01
CA3150751A1 (en) 2021-02-18
KR20220046625A (ko) 2022-04-14
AU2020328351A1 (en) 2022-03-24
JP2022180531A (ja) 2022-12-06
WO2021029430A1 (ja) 2021-02-18
JPWO2021029430A1 (https=) 2021-02-18
EP4015002A4 (en) 2023-06-07
AU2020327792B2 (en) 2026-03-05
TWI870441B (zh) 2025-01-21
CA3150827A1 (en) 2021-02-18
IL290472A (en) 2022-04-01
IL290469B2 (en) 2025-08-01
TW202120091A (zh) 2021-06-01
IL290469B1 (en) 2025-04-01
CN114222562A (zh) 2022-03-22
WO2021029429A1 (ja) 2021-02-18
BR112022002436A2 (pt) 2022-12-13
TW202517267A (zh) 2025-05-01
MX2025006039A (es) 2025-07-01
EP4015001A4 (en) 2023-06-14
JP7148733B2 (ja) 2022-10-05
JP2025072595A (ja) 2025-05-09
TWI870442B (zh) 2025-01-21
MX2022001759A (es) 2022-05-13
JP2022132411A (ja) 2022-09-08
EP4015002A1 (en) 2022-06-22
JP2025074104A (ja) 2025-05-13
IL290469A (en) 2022-04-01
WO2021029020A1 (ja) 2021-02-18
ZA202202319B (en) 2024-06-26
TW202517266A (zh) 2025-05-01
US20250057835A1 (en) 2025-02-20
KR20220046624A (ko) 2022-04-14
EP4015001A1 (en) 2022-06-22
US20220273647A1 (en) 2022-09-01
US20250127776A1 (en) 2025-04-24
US20220280418A1 (en) 2022-09-08
JP7110495B2 (ja) 2022-08-01
ZA202202320B (en) 2024-06-26
AU2020328351B2 (en) 2026-03-05
PH12022550349A1 (en) 2022-12-12
JP7635187B2 (ja) 2025-02-25

Similar Documents

Publication Publication Date Title
ZA202202319B (en) Oral pharmaceutical composition
EP4512394A3 (en) Dosage forms and use thereof
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
EP3706741A4 (en) PHARMACEUTICAL COMPOSITION AND USE THEREOF
PE20180411A1 (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
EP3946547A4 (en) DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS
WO2018165404A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
MX2020003088A (es) Composicion medicinal que comprende el inhibidor del sglt2 y el antagonista del receptor de angiotensina.
EP2493312A4 (en) Solid pharmaceutical compositions containing an integrase inhibitor
IL291543A (en) Medical preparations and their use
MX2019001771A (es) Composición farmacéutica sólida que comprende el sofosbuvir amorfo.
ZA202003904B (en) Drug delivery system
EP4017496A4 (en) FORMULATIONS FOR THE PREVENTION AND/OR TREATMENT OF PERIPHERAL NEUROPATHY AND ITS ASSOCIATED DISEASES
MX2020003513A (es) Composiciones de ingredientes activos que comprenden n-alquenoil-n-alquilglucamidas y el uso de los mismos.
IL319382A (en) Pharmaceutical preparation and its use
MX2018000963A (es) Composicion farmaceutica sinergica del enantiomero activo s-ketorolaco trometamina y clorhidrato de tramadol.
PH12022550093A1 (en) Dose dumping resistant pharmaceutical compositions comprising verinurad
MX2021004553A (es) Composiciones farmaceuticas y metodos para fabricar formulaciones de dosificacion solidas bajo demanda.
WO2020032883A3 (en) Synergistic effects of a novel ketoprofen formulation including a gastro protective agent
EA202092800A1 (ru) Фармацевтическая композиция немедленного высвобождения для противовоспалительных лекарственных средств с фамотидином и карбонатом
EP4389147A3 (en) Therapeutic formulations and uses thereof
WO2020013776A3 (en) Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation
WO2019203759A3 (en) Combinations of etodolac with h2 receptor antagonists for the treatment of pain and inflammation.
PH12020550456A1 (en) Alcohol-resistant oral pharmaceutical compositions of lorazepam
TR201714149A2 (tr) Ulipristal asetat içeren bir tablet formülasyonu.